'Sunshine Act' Gets Guarded Reaction
The "National Physician Payment Transparency Program: Open Payments"—was mandated under the Affordable Care Act to improve transparency in the healthcare market. The final rule was scheduled to be published 15 months ago and federal officials this week offered no explanation for the late issue, which comes three months after the November election.
"You should know when your doctor has a financial relationship with the companies that manufacture or supply the medicines or medical devices you may need," Peter Budetti, MD, deputy administrator for Program Integrity at the Centers for Medicare and Medicaid Services, said in a media release. "Disclosure of these relationships allows patients to have more informed discussions with their doctors."
'Sunshine Act' Final Rule
The rule requires makers of drugs, devices, medical supplies, and biotech firms covered by Medicare, Medicaid, or the Children's Health Insurance Program to disclose payments or other "transfers of value" to doctors and teaching hospitals.
It also requires manufacturers and group purchasing organizations to disclose to CMS physician ownership or investment interests. CMS will post the data on a public website next year. Budetti says more transparency will reduce the potential for conflicts of interest that physicians or teaching hospitals face because of their relationships with manufacturers.
Data collection will begin on Aug. 1, 2013. Manufacturers and GPOs will report the data for August through December of 2013 to CMS by March 31, 2014 and CMS will make the data public by Sept. 30, 2014.
- How Top-Ranked MA Plans Earn Their Stars
- Readmissions: No Quick Fix to Costly Hospital Challenge
- How Hospitals Can Become 'Upstreamists'
- 4 Ways to Lower the Cost to Collect from Self-Pay Patients
- House Calls Key to Pioneer ACO Success
- How Telehealth Pays Off for Providers, Patients
- 4 Tips for Managing Employed Physicians
- Defensive Medicine Still Prevalent Despite Tort Reform
- WellPoint Dominates Nearly Half of Markets, AMA Says
- 'Overtreatment' Debate Circles Back to Lung Cancer Screening